Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Carboplatin/Taxane ± Maintenance Olaparib in First-line Metastatic Squamous NSCLC
2023-508449-41-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in Pulmonary squamous cell carcinoma (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free Survival (PFS) per RECIST 1.1 and Overall Survival (OS). Started Mar 2024; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2023-508449-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508449-41-00.